Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 1801-1810 Newer>

The Motley Fool February 25, 2005 Stephen D. Simpson	Will VCA Antech Go to the Dogs? The veterinary service provider has growth, but lots of debt too.
The Motley Fool February 25, 2005 Charly Travers	Protein Design Labs' Future A look ahead to a transitional year -- and how much the ESP Pharma acquisition will boost revenues -- coming Monday.
The Motley Fool February 25, 2005 Brian Gorman	Omnicare's Grace Under Pressure The pharmacy services provider is responding well to the challenges in its business.
The Motley Fool February 24, 2005 Charly Travers	Transkaryotic's Turnaround This biotech spotlights superb management creating shareholder value.
The Motley Fool February 23, 2005 Stephen D. Simpson	LCA-Vision Focuses on Profit The provider of laser vision correction is aggressive, but the market is ripe for consolidation. Despite the company's rocketing growth and an equally hot stock, valuation isn't too bad.
The Motley Fool February 23, 2005 Stephen D. Simpson	Take Two on COX-2 FDA panel recommendations breathe new life into Merck and Pfizer's COX-2 pain medications. Looking ahead, investors should give a good, long look to the drug sector.
The Motley Fool February 23, 2005 Charly Travers	QLT Is Still a Value The market's concerns mean this Canadian drug company is being offered up at a great price.
The Motley Fool February 23, 2005 Brian Gorman	Amgen Gets Disciplined Direct-to-consumer advertising may be a non-starter for Amgen and other biotech companies.
The Motley Fool February 23, 2005 Stephen D. Simpson	Making Short Work of Surgery United Surgical Partners prospers by working with hospitals instead of against them. While valuation isn't cheap, that has to be considered in the context of a company that is growing at a 30%-plus clip.
The Motley Fool February 22, 2005 Charly Travers	Is Big Pharma a Bargain? While much of the drug sector is looking pretty tasty, Pfizer, with its attractive relative valuation, dominant marketing presence, and willingness to buy up blockbuster drugs, heads the list.
<Older 1801-1810 Newer> Return to current articles.